A Phase 1/2 Clinical Trial to Evaluate HST-003 in Combination with a Microfracture Procedure in Civilian and Military Patients with Recent Focal Cartilage Defects in the Knee Caused by Injury
Latest Information Update: 18 Nov 2022
At a glance
- Drugs HST 003 (Primary)
- Indications Cartilage disorders
- Focus Adverse reactions; Therapeutic Use
- 10 Nov 2022 According to a Histogen media release, the company has implemented protocol modifications in the third quarter of 2022 and expect to complete feasibility evaluation in the fourth quarter of 2022.
- 12 May 2022 According to a Histogen media release, the company added three additional clinical sites to help supplement enrollment of patients due to the recruitment challenges that company experienced related to both the specific nature of the study inclusion criteria and the impact of COVID-19 on the elective surgery environment in first quarter of 2022.
- 10 Mar 2022 According to a Histogen media release, top-line results from this study are anticipated in the first half of 2023, assuming enrollment completion in the fourth quarter of 2022.